The Manufacturers Life Insurance Company Has $179,000 Stock Position in Altimmune, Inc. (NASDAQ:ALT)

The Manufacturers Life Insurance Company lifted its holdings in shares of Altimmune, Inc. (NASDAQ:ALT) by 30.7% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 26,973 shares of the company’s stock after purchasing an additional 6,339 shares during the period. The Manufacturers Life Insurance Company’s holdings in Altimmune were worth $179,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of ALT. DRW Securities LLC acquired a new position in shares of Altimmune in the second quarter worth approximately $112,000. XTX Topco Ltd bought a new stake in shares of Altimmune in the 2nd quarter valued at $96,000. Dimensional Fund Advisors LP boosted its stake in shares of Altimmune by 142.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock valued at $3,791,000 after purchasing an additional 335,444 shares during the last quarter. PFG Investments LLC acquired a new stake in shares of Altimmune during the second quarter worth $67,000. Finally, Los Angeles Capital Management LLC bought a new position in Altimmune during the second quarter worth $689,000. Institutional investors own 78.05% of the company’s stock.

Insider Buying and Selling at Altimmune

In other Altimmune news, Director David Drutz sold 16,011 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $6.90, for a total transaction of $110,475.90. Following the completion of the sale, the director now directly owns 41,958 shares of the company’s stock, valued at approximately $289,510.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 4.10% of the company’s stock.

Altimmune Price Performance

Shares of Altimmune stock opened at $6.88 on Friday. The business has a 50-day simple moving average of $6.72 and a 200 day simple moving average of $6.96. The firm has a market capitalization of $487.81 million, a price-to-earnings ratio of -4.33 and a beta of 0.08. Altimmune, Inc. has a one year low of $2.09 and a one year high of $14.84.

Altimmune (NASDAQ:ALT) last issued its earnings results on Thursday, August 8th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). Altimmune had a negative return on equity of 53.09% and a negative net margin of 24,778.97%. The firm had revenue of $0.01 million for the quarter. During the same quarter last year, the firm earned ($0.32) earnings per share. On average, sell-side analysts expect that Altimmune, Inc. will post -0.54 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ALT shares. B. Riley reiterated a “buy” rating and set a $20.00 price target on shares of Altimmune in a report on Monday, August 12th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Altimmune in a research note on Thursday, August 22nd. Finally, Evercore ISI raised Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $18.80.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.